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ABSTRACT Pneumococcalmeningitiscanleadtodeathorseriousneurologicalsequelaeasaresultofthehostinﬂammatoryre-
sponse.Weinvestigatedtheassociationbetweenhostresponseproteinexpressionandoutcomeinpatientswithpneumococcal
meningitis.Cerebrospinalﬂuid(CSF)wasobtainedfrom80patientswithpneumococcalmeningitis(40nonsurvivorsand40
survivors)and10normalcontrols.Candidateproteinswereanalyzedforanassociationwithsurvival.ComplementC3levels
were5-foldlowerinnonsurvivorsthaninsurvivors(P<0.05).ThisC3reductionwasnotassociatedwithlowerlevelsinserum,
indicatingacompartmentalizedCSFresponse.TransferrinlevelsweresigniﬁcantlyhigherinCSF(butnotserum)fromnonsur-
vivorsthaninCSFfromsurvivors,suggestiveofblood-brainbarrierdamage.Classicalapoptosisproteinscaspase3and
apoptosis-inducingfactorwerenotpresentinCSF.ExpressionofcreatinekinaseBBinclinicallyinfectedCSFsuggestedneuro-
nalnecrosis,buttherewasnoclearassociationbetweenlevelofexpressionandclinicaloutcome.Increasedblood-brainbarrier
permeabilityandcomplementC3depletionmayhavearoleindeterminingoutcomefrombacterialmeningitis.Therapeuticuse
ofciticolineorcaspaseinhibitorsisunlikelytohavebeneﬁcialeffectsinpatientswithmeningitis.
IMPORTANCE Wepreviouslyidentiﬁedproteinsassociatedwithclinicaloutcomeinpatientsdiagnosedwithpneumococcalmen-
ingitisinapilotproteomicsstudyofcerebrospinalﬂuid(CSF).Inthisarticle,wehavequantitativelyassayedspeciﬁcproteins
identiﬁedfromthispreviousproteomicsanalysisalongwithproteinsassociatedwithcelldeathbyusingWesternblotting.
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D
espite many major advances in our understanding of the
pathogenesisofpneumococcalmeningitis,therehasbeenlit-
tletherapeuticprogressinthelast60years.Thisispredominantly
due to the fact that bacterial cell wall products released in the
cerebrospinal ﬂuid (CSF) initiate a cascade of destructive host
immuneresponsesthatarenotamelioratedbycurrentlyavailable
treatments.
We have shown that complement C3 depletion and increased
blood-brain barrier permeability may have a role in determining
the outcome of bacterial meningitis. In addition, therapeutic use
of citicoline or caspase inhibitors is unlikely to have a beneﬁcial
effect in patients with meningitis, as these pathways were not de-
monstrably disrupted.
Streptococcus pneumoniae is the most common pathogen asso-
ciatedwithbacterialmeningitisbeyondtheneonatalperiod(1).In
Malawi, pneumococcal meningitis has a high fatality rate of 67%
(2). Survivors often develop long-term neurological sequelae, in-
cluding hearing loss and focal neurological deﬁcits (3, 4). Our
previous pilot proteomic study of CSF in patients with pneumo-
coccal meningitis revealed that clinically infected CSF contains
several thousand proteins of central nervous system (CNS) and
serum origin. A proteomic comparison of nonsurvivors and sur-
vivorsalloweddetectionofproteinsassociatedwithsurvival(5).It
was therefore necessary to determine if this correlation, and sub-
sequent hypotheses generated, could be conﬁrmed in a larger
sample size.
CSFproteinsoriginatefromserumandfromlocalintracranial
production. A breakdown in the integrity of the blood-brain bar-
rier allows increased levels of serum proteins to access the CSF
(6–8). This contributes to the development of increased intracra-
nial pressure, hydrocephalus, brain edema, and cerebral ischemia
(9, 10), all of which can cause neuronal cell death (11, 12). In
animal models, cell death was found to occur via three distinct
pathways: classic caspase 3-dependent cell death (i.e., apoptosis),
caspase3-independentcelldeath(i.e.,pyknosis),andnecrosis(13,
14). Caspase inhibitors and citicoline, an intermediate in the syn-
thesis of phosphorylcholine in mitochondrial and cell mem-
branes, prevented neuronal damage when given before and after
bacterialinfectioninanimalmodelsofmeningitis.Theseproducts
might be used therapeutically for protection against neuronal cell
death by apoptosis if this mechanism was shown to be important
inhumans(15–17).Accurateidentiﬁcationofproteinsassociated
with speciﬁc mechanisms of neuronal cell death in human CSF
could therefore provide evidence to support clinical trials of anti-
apoptotic drugs for improved patient outcome.
Inourpreviousstudy,wefoundreducedcomplementC3levels
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central role in the activation of the complement system. Process-
ing by C3 convertase is the central reaction in both classical and
alternativecomplementpathways.C3aidsinnateimmunityeither
by the coating of pathogens with C3b and iC3b, which stimulates
phagocytosis,orbythereleaseofproinﬂammatorymediatorsC3a
and C5a (18). Pathological sequelae are mediated in part by the
intrathecal activation of the complement cascade in response to a
bacterial challenge (19). The relationship between complement
C3 activity and pneumococcal meningitis is not fully understood.
Classical and lectin pathways are most commonly associated with
pneumococcal disease (20). Many pathogenic serotypes of pneu-
mococci are poor activators of the alternative complement path-
way (21) or degrade C3b into less opsonically active components
(22)andarethereforeabletoresistphagocytosis.Theimportance
of opsonization, however, is strongly supported by the ﬁnding
that the impairment of either the phagocytic system or opsonin
production predisposes the host to pneumococcal disease (23,
24).
This study tested three hypotheses: (i) candidate proteins pre-
viouslyidentiﬁedbypilotproteomicscanbeconﬁrmedinalarger
comparisonofsurvivorsandnonsurvivors,(ii)apoptoticproteins
inCSFareassociatedwithdeath,and(iii)necrosisproteinsfound
in pneumococcal meningitis-affected CSF are associated with
death.
RESULTS
Clinical details of patients. CSF from 80 patients with microbio-
logicallyprovenpneumococcalmeningitiswasanalyzedbyWest-
ern blotting. Forty of these CSF samples were from patients who
survivedwithnoneurologicalimpairment.Theremaining40sub-
jects all died within 10 days. Clinical details of the patients are
provided in Table 1.
CSF total protein concentration. CSF from patients with
meningitis had a mean total protein concentration of 5.92 mg li-
ter1 compared to control (mean, 0.23 mg liter1; P  0.0001).
Nonsurvivorshadatotalproteinconcentrationbetween2.20and
11.30 mg liter1 (mean, 6.38 mg liter1). Survivors had a total
protein concentration between 1.12 and 10.89 mg liter1 (mean,
5.46mgliter1).Themeantotalproteinconcentrationwashigher
in nonsurvivors than in survivors, but the two concentrations
were not signiﬁcantly different (P  0.09; see Fig. S1 in the sup-
plemental material).
Expression of proteins of plasma origin in cerebrospinal
ﬂuid. (i) Expression of transferrin in cerebrospinal ﬂuid and
blood serum. Transferrin was measured in normal CSF (mean,
0.08 mg liter1), nonsurvivor CSF samples (mean, 1.25 mg li-
ter1),andsurvivorCSFsamples(mean,0.67mgliter1)(Fig.1).
The mean concentration of transferrin in normal CSF was signif-
icantlylowerthanthatinCSFfrompatientsdiagnosedwithmen-
ingitis (P  0.0001). The mean concentration of transferrin in
CSF from nonsurvivors was 2-fold higher than that in CSF from
survivors (P  0.0004).
Transferrin was measured in serum samples from nonsurvi-
vors(mean,1.72mgliter1)andsurvivors(mean,1.89mgliter1;
TABLE 1 Clinical details of survivors and deceased patientsa
Parameter
Subject group (n)
Normal (10) Nonsurvivors (40) Survivors (40)
Age, yr [mean (SD)] 27.8 (9.5) 30.1 (8.4) 33.3 (11.2)
Male sex, n 32 3 1 6
GCS [median (SD)] 9.0 (4.7) 8.0 (3.2) 11.0 (3.2)
Median time to presentation [h (range)] 60 (12–96) 72 (15–336) 48 (10–192)
Previous antimicrobials, no. 2 7 6
Steroid treatment [no. receiving (no. receiving placebo)] 17 (23) 21 (19)
HIV positive [no. (% of those tested)] 35 (100) 37 (100)
HIV status not known, no. 10 5 3
Survival at day 10, % 100 0 100
Hemoglobin [g/dl (range)] 10.82 (2.8–15) 11.01 (5.5–17.7)
CSF leukocytes [count/l (range)] 1,376.3 (20–9,980) 2,088.4 (15–10,500)
Neutrophils [count (% of those tested)] 92.17 (67–100) 91.97 (76–99)
a Clinical data collected from patients providing CSF samples that were used in this analysis. All meningitis subjects were diagnosed as having pneumococcal meningitis caused by
Streptococcus pneumoniae, all subjects were HIV positive, and all samples were collected before any treatment commenced. Normal CSF was obtained from patients who tested
negative for meningitis or any other pathogen. The HIV status of the normal patients was not known. Hemoglobin levels have been included as low hemoglobin levels are
associated with both advanced AIDS and poor outcome. GCS, Glasgow coma scale.
FIG 1 Transferrin levels in CSF. Transferrin was measured in normal CSF
(mean, 0.08 mg liter1). Transferrin was found in nonsurvivor CSF samples
(mean, 1.25 mg liter1) and survivor CSF samples (mean, 0.67 mg liter1).
Therewasastatisticallysigniﬁcantdifferencebetweenthemeanleveloftrans-
ferrin in nonsurvivors and that in survivors (P  0.0004). The mean level of
transferrin in nonsurvivor CSF was 2-fold higher than that in survivor CSF.
Therewasastatisticallysigniﬁcantdifferencebetweenthemeanleveloftrans-
ferrin in meningitis-affected CSF and that in normal CSF (P  0.0001).
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for correlation between the concentration of transferrin in serum
from patients and the corresponding CSF concentration in both
nonsurvivors and survivors and found none (see Fig. S3 and S4).
The mean concentration of transferrin in serum from nonsurvi-
vors was 1.5-fold higher than the corresponding level in CSF, but
the mean concentration of transferrin in survivors was 3-fold
higher in serum than in the corresponding CSF.
(ii)ExpressionofcomplementC3incerebrospinalﬂuidand
serum. Complement C3 was not found in normal CSF. C3 levels
in nonsurvivor CSF samples (mean, 0.04 mg liter1) were signif-
icantly lower than those in survivor CSF samples (mean,
0.21 mg liter1; P  0.0001) (Fig. 2).
There was no statistically signiﬁcant difference between the
mean concentration of C3 in serum of nonsurvivors (mean,
1.47 mg liter1) and that in the serum of survivors (mean,
1.50 mg liter1; P  0.81) (see Fig. S5 in the supplemental mate-
rial). There was a statistically signiﬁcant difference between the
mean concentrations of C3 in CSF and in the corresponding se-
rum samples (P  0.0001) see Fig. S6 and S7).
(iii) Expression of beta-2-glycoprotein in cerebrospinal
ﬂuid. Beta-2-glycoprotein was measured in normal CSF (mean,
0.13 mg liter1), nonsurvivor CSF samples (mean, 0.83 mg li-
ter1), and survivor CSF samples (mean, 0.69 mg liter1). There
wasasigniﬁcantdifferencebetweenthemeanbeta-2-glycoprotein
levelsinCSFfrompatientsdiagnosedwithpneumococcalmenin-
gitis and those in normal CSF (P  0.0001) but not between non-
survivors and survivors (P  0.10).
Cerebrospinal ﬂuid levels of apoptosis proteins. Neither
caspase 3 nor apoptosis-inducing factor (AIF) was detected in the
80 meningitis-associated CSF samples (nonsurvivors or survi-
vors)orthe10normalCSFsamples(seeFig.S8inthesupplemen-
tal material). Western blotting for both caspase 3 and AIF was
repeated with two primary antibodies directed against different
regions of the respective protein structures with the same out-
come. The speciﬁcity of the antibodies was conﬁrmed using an
antigenic blocking peptide. The blocking peptide binds to the ac-
tivesiteoftheantibody,whichinhibitstheantibodyactivity,lead-
ing to quenching of protein expression. The sensitivity of detec-
tion was increased by the use of polyclonal antibodies directed
against caspase 3 and AIF at optimum levels of concentration and
exposure to the CSF proteins.
The limit of detection was determined by serial dilution of the
positive control. Both AIF and caspase 3 were detectable in the
positivecelllysateatproteinconcentrationsaslowas100ngl1.
ThevisualizationoftheproteinsinCSFuponspikingnormalCSF
with the control lysate would suggest that the proteins are not
being confounded by larger proteins in CSF (see Fig. S9 in the
supplemental material).
CerebrospinalﬂuidlevelsofthenecrosisproteinCKBB.Cre-
atine kinase BB (CKBB) was not detected in normal CSF samples
but was present in over 40% of CSF samples from patients diag-
nosedwithmeningitis.ThemeanconcentrationsofCKBBinnon-
survivors and survivors were 0.89 mg liter1 and 0.19 mg liter1,
respectively, but there was no statistically signiﬁcant difference
betweenthetwogroups(P0.16),owingtothesmallnumberof
samples with detectable CKBB as shown in Fig. 3.
Proteomic candidate cerebrospinal ﬂuid markers of clinical
outcome. Retinoid X receptor (RXR) gamma was not found in
normal CSF but was found in 73% of nonsurvivor CSF samples
(mean, 0.50 mg liter1, inclusive of all samples) and 83% of sur-
vivorCSFsamples(mean,0.36mgliter1,inclusiveofallsamples;
P  0.48).
Zinc ﬁnger protein 179 was not found in normal CSF but was
foundin98%ofnonsurvivorCSFsamples(mean,0.52mgliter1,
inclusiveofallsamples)and70%ofsurvivorCSFsamples(mean,
0.41 mg liter1, inclusive of all samples; P  0.59).
Chitotriosidase was not found in normal CSF. Chitotriosidase
wasfoundin50%ofnonsurvivorCSFsamples(mean,0.88mgli-
FIG 2 Complement C3 levels in CSF. C3 was not found in normal CSF (n 
10).C3wasfoundinnonsurvivorCSFsamples(n40;mean,0.04mgliter1)
and survivor CSF samples (n  40; mean, 0.21 mg liter1). There was a statis-
ticallysigniﬁcantdifferencebetweenthemeanconcentrationofC3innonsur-
vivorsandthatinsurvivors(P0.0001).ThemeanlevelofC3innonsurvivor
CSF was 5-fold lower than that in survivor CSF.
FIG3 CreatinekinaseBBlevelsinCSF.CKBBwasdiscoveredinover40%of
the CSF samples. CKBB levels were not signiﬁcantly higher in nonsurvivors
(mean, 0.89 mg liter1, inclusive of all samples) than in survivors (mean,
0.19 mg liter1, inclusive of all samples) (P  0.16). CKBB was not found in
normal CSF.
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(mean, 0.47 mg liter1, inclusive of all samples; P  0.09).
DISCUSSION
In our previous pilot proteomic analysis of CSF in patients diag-
nosed with pneumococcal meningitis, we observed several pro-
teinshavinganassociationwithsurvival(5).Inthisstudy,wehave
shown that a subset of these proteins were detectable in a larger
sample size; however, only the proteins transferrin and comple-
ment C3 showed a signiﬁcant association with survival.
Blood-brain barrier integrity and transferrin. The blood-
brain barrier is responsible for maintaining biochemical homeo-
stasis within the CNS (25). Penetration of the blood-brain barrier
by a bacterial pathogen reﬂects a complex interplay between the
host endothelium and microbial surface components (26).
Transferrinisresponsibleforthetransportofironfromsitesof
absorption and heme degradation to those of storage and utiliza-
tion (27, 28). The increased level of transferrin in nonsurvivors
was an indicator of blood-brain barrier damage, and this damage
mayhavebeenacontributingfactortodeathfrompneumococcal
meningitis.Theobservation,however,thatCSFlevelsdidnotcor-
relatewithserumlevelsimpliesthat,althoughtransferrinlevelsin
CSF relate to blood-brain barrier integrity and simple diffusion,
there has not been a complete breakdown of the blood-brain bar-
rier regulation of proteins in most cases.
Another possible explanation for the lack of association be-
tween CSF and plasma transferrin levels may be the negative
acute-phasepropertyoftransferrin,i.e.,transferrinhasatendency
to decrease during inﬂammation and CSF/serum time courses of
transferrin regulation are likely not synchronous (27).
This partial breakdown of the blood-brain barrier correlated
with the observation that the levels of the serum protein beta-2-
glycoprotein(importantinprocessessuchascoagulationandath-
erosclerosis) did not vary between nonsurvivors and survivors,
indicatingthattheblood-brainbarrierretainssomeabilitytoﬁlter
serum (29).
Complement C3 depletion and outcome. Complement C3
was observed to be lower in nonsurvivors than in survivors. To
conﬁrm that this change in C3 concentration was localized to the
CNS, analysis was carried out on corresponding blood samples.
The lack of any association between C3 in serum and that in CSF
indicated that changes in the level of C3 were localized to CSF.
The ﬁrst evidence for a functional role of the complement sys-
tem in limiting pneumococcal outgrowth within the CNS was
described by Tuomanen et al. (23). In rabbits depleted of C3 by
cobra venom factor, intracisternal inoculation of S. pneumoniae
resulted in higher bacterial titers than those in complement-
sufﬁcient control animals (30). Thus, lower levels of C3 in non-
survivors than in survivors may have resulted in higher bacterial
titersormayhavebeenduetogreaterconsumptionofC3inmore
severe illness. A positive-feedback mechanism can be proposed
where nonsurvivors had very high numbers of bacterial CFU in
their CSF, which led to activation and breakdown of C3. Some
pneumococcalspeciescandegradeC3directly;forexample,Angel
et al. demonstrated that type 3 pneumococci express C3-
degradingactivityassociatedwiththecellwall(22,31).Fewofthe
infections in this study were due to type 3, however, as this type is
not common in Malawi (32).
Patients were recruited at the point of admission to the hospi-
tal. Clinical information indicative of AIDS preceding the acute
episode was sought in all patients. Twenty-four patients had evi-
denceofchronicillnessoroneormoreHIV-associatedinfections
(11 had a history of tuberculosis [TB] treatment, 10 had shingles,
3hadpneumonia,and3hadmeningitis).Wecanonlyspeculateas
tothenatureoftheeffectofHIVandofencephalopathycausedby
HIV on the ﬁnal results, as CNS HIV infection and immune acti-
vation have been demonstrated to also lead to brain injury (33).
Serum albumin levels are used to distinguish viral meningitis
frombacterialmeningitisinCSF(34).Unfortunately,thealbumin
datafrompatientswerenotavailableowingtothelimitedhospital
laboratory support available at the study site. These albumin data
couldhavebeenusedtocomparethebloodplasmalevelswiththe
ﬁnal CSF levels. This would allow a measure of the compartmen-
talization of the CSF protein changes and also a measure of the
effect of viral infection prior to meningitis.
Cell death markers in cerebrospinal ﬂuid. Despite animal
models indicating that caspase 3 and AIF would be detectable in
CSF during pneumococcal meningitis in humans (17, 35, 36),
there was no evidence observed of these classical apoptosis mark-
ers. The data obtained from the analysis of apoptosis proteins
indicatethatsincecaspase3andAIFarenotpresent,therewasno
leakage of cell death material into CSF. This was surprising con-
sideringthelevelofdatainanimalmodelswhichsuggestthatthese
proteinswouldbeidentiﬁedinCSF.Itwaspossible,however,that
thesewerelonger-termanimalmodelswherethelevelsofbacteria
and pneumolysin were lower than those in the nonsurvivor
groups analyzed in this study (35, 37).
Itwasalsopossiblethatsmallfociofapoptosisdidnotresultin
a large increase of caspase 3 or AIF, and this could be conﬁrmed
with suitable postmortem material. Alternatively, an increase in
metabolic proteins, previously identiﬁed in the pilot proteomics
analysis (5), may have led to an increase in proteosomal degrada-
tionofAIFandcaspase3.Thesedegradationpathwaysmayoccur
via a ubiquitination process such as that mediated by X-linked
inhibitorofapoptosis(XIAP)utilizingE3ubiquitinligaseactivity.
This enables apoptosis inhibitors to catalyze ubiquitination of
themselves, caspase 3, caspase 7, and AIF (38).
Caspaseinhibitorsandciticolinemayhaveneuroprotectiveef-
fects and may potentiate neurorecovery. This has led to the eval-
uation of caspase inhibitors and citicoline as potential treatment
for neuronal injury during meningitis. On the basis of our data,
however, there is no theoretical rationale for the use of caspase
inhibitorsorciticolineinpatientswithpneumococcalmeningitis.
Further exploration may require development of an in vitro
model of the CSF inﬂammatory process to determine if CSF from
nonsurvivors causes injury to neurons and endothelial cells more
than does that from survivors. The addition of caspase inhibitors
to this model can be used to see if a difference is observed. Anti-
apoptosis treatment could be used to determine if the lack of
caspase or AIF in CSF is related to tissue damage. This will allow
the opposite conclusion to be validated.
Inrodentmodels,neuronalnecrosishasbeenshowntoinvolve
caspase 3 and AIF (39). Therefore, the absence of these proteins
provides evidence that necrosis also does not occur at signiﬁcant
levels. To distinguish necrosis from apoptosis, we used creatine
kinase as a speciﬁc marker of neuronal necrosis. CKBB is the
brain-speciﬁc isotype of the protein (40). This protein is a cyto-
plasmicproteinreleasedduringtissuenecrosis.CKBBcanleakout
of cells under ischemic episodes or injury to the brain (41). Our
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pneumococcal meningitis.
Proteinsofcerebrospinalﬂuidoriginshowednoassociation
with outcome. The proteins analyzed as indicators of proteins in
CSFincludedRXRgamma,zincﬁngerprotein179,andchitotrio-
sidase. RXR gamma receptors are involved in the expression of
anti-inﬂammatory activity by immune cells and mediate the cel-
lulareffectsofretinoidcompounds(42).Zincﬁngerprotein179is
predominantly expressed in the brain. The gene for this protein
encodesamemberoftheRINGﬁngerproteinfamilyoftranscrip-
tion factors and is associated with neuronal differentiation. The
protein has been implicated in a variety of functions such as tran-
scriptional regulation, DNA repair, site-speciﬁc recombination,
andsignaltransduction(43).RXRgammaandzincﬁngerprotein
179arelocatedprimarilyinthenucleus.Theirlow-leveldetection
maybeduetoanincompleteleakageofcellmaterialintotheCSF,
although the similar levels of these proteins suggest that their ex-
pression has no clear association with outcome (42, 43).
Chitotriosidase is an enzyme which degrades chitin and chito-
triose and may participate in the defense against nematodes and
other pathogens (44). Chitotriosidase can be considered an in-
ﬂammatory protein since it is secreted only by activated macro-
phages and may be used as an important predictor of neuronal
disease severity (45). It was expected that chitotriosidase would
have greater expression in CSF associated with clinically proven
pneumococcal meningitis, but the expression was very low or ab-
sent.
Conclusions. This study has shown that blood-brain barrier
damage appears to alter the level of protein in CSF and acts as a
confounding factor in protein analysis of the CNS during menin-
gitis. The increased level of transferrin in nonsurvivors suggested
blood-brain barrier damage but did not provide a direct marker
for the degree of damage.
In addition, this study has shown that CSF levels of comple-
ment C3 are associated with outcome in pneumococcal meningi-
tis. The data suggest that complement C3 plays an important role
in the pathogenesis of bacterial meningitis and may serve as a
prognostic marker.
The absence of standard apoptosis markers in CSF suggested
that treatment involving citicoline and caspase inhibitors is un-
likely to provide beneﬁt to patients with pneumococcal meningi-
tis. The presence of CKBB indicated that cortical necrosis occurs
to a signiﬁcant degree in many patients with pneumococcal men-
ingitis, but this was not clearly associated with outcome.
MATERIALS AND METHODS
Patient information. (i) Patients and sample collection. Patients were
recruitedtoadouble-blind,randomized,placebo-controlledtrialofdexa-
methasone adjuvant therapy. CSF and blood serum samples collected
from patients as part of clinical diagnosis were saved for later study. The
study was conducted in adults with bacterial meningitis presenting at the
QueenElizabethCentralHospitalinBlantyre,Malawi,betweenMay2002
and January 2005 (46). The study was approved by the research ethics
committees of the University of Malawi College of Medicine and the Liv-
erpool School of Tropical Medicine. Patients provided written informed
consent, or if they were unable to read or write, they provided indepen-
dentlywitnessedverbalconsentbeforerecruitment.Patientsweretreated
in the hospital for a minimum of 10 days and were evaluated at 40 days
and at 6 months. Clinically evident adverse events were recorded system-
aticallythroughoutthetrialperiod.Atfollow-up,patientshadastandard-
ized neurologic examination and a hearing assessment. Patients who did
not return for follow-up appointments were visited at home. No other
underlying diseases were speciﬁcally sought other than HIV and malaria
(46).
(ii) Patient categories. Clinical data allowed the patients in the men-
ingitistrialtobeclassiﬁedinto3clearphenotypes:survivalto40dayswith
no neurological impairment or recorded disability (n  103), deafness or
disability at 40 days (n  113), and death within 40 days (n  157). We
chose to study only patients who had conﬁrmed pneumococcal meningi-
tis (Gram-positive diplococci seen in CSF or pneumococci cultured from
either CSF or blood) and to compare those who survived free of neuro-
logical deﬁcit with those who died, as we anticipated that these pheno-
typeswouldshowtheclearestdifferences.ControlCSFwasobtainedwith
consent from patients who presented to the hospital with a headache but
subsequently tested negative for meningitis or any other pathogen. CSF
samples were stored at 20°C within an hour of sampling and at 80°C
from 24 h until analysis.
Protein target selection. (i) Proteomically derived targets. Proteins
werepreviouslyidentiﬁedashavingdifferentlevelsofexpressionbetween
nonsurvivors and survivors in a pilot proteomic comparison of CSF (5).
These proteins were formally identiﬁed after manual excision from
stained two-dimensional (2D) gels. The proteins were subject to in-gel
tryptic digestion and sequenced by matrix-assisted laser desorption ion-
ization–time of ﬂight (MALDI-TOF) mass spectrometry (MS) or liquid
chromatography (LC)-MS. Peptide data were analyzed with Mascot soft-
ware (Matrix Science, London, United Kingdom). In this comparison of
CSFfrompatientswhosurvivedwithCSFfromthosewhodied,wechose
to compare speciﬁc proteins that showed important differences (3-fold
expression)inexploratory2Dgelanalysis.Thetargetsselectedfromthese
proteins for further analysis included three proteins of plasma origin and
three proteins of CSF origin. The three plasma proteins analyzed were (i)
transferrin, (ii) complement C3, and (iii) beta-2-glycoprotein. The three
proteins of cerebrospinal ﬂuid origin analyzed were (i) retinoic acid X
receptor gamma, (ii) zinc ﬁnger protein 179, and (iii) chitotriosidase.
(ii) Cell death pathway targets. Proteins associated with apoptosis
and necrosis were analyzed in CSF. We analyzed CSF for the apoptosis-
associated proteins apoptosis-inducing factor (AIF) and caspase 3 (35).
WeanalyzedCSFfortheproteincreatinekinaseBB(CKBB)asevidenceof
neuronal necrosis (45).
Westernblottingofcerebrospinalﬂuid.ArchivedCSFwasthawedat
4°C. The concentration of protein in each CSF sample was determined
using the Bradford assay. SDS-PAGE gels of whole CSF protein were sep-
arated using optimized gel concentrations for each Western blot. The
transfer membranes used in all the experiments of this analysis were ni-
trocellulose paper (NCP; GE Life Sciences, Piscataway, NJ). AIF and
caspase 3 protein blots were retested using polyvinylidene diﬂuoride
(PVDF) membranes (GE Life Sciences).
(i) Antibodies. Primary antibodies used in this analysis were directed
against caspase 3 (9665 and sc-22140) and apoptosis-inducing factor
(AIF;4642andsc-9416)andcamefromCellSignaling(Danvers,MA)and
Santa Cruz Biotechnology (Santa Cruz, CA). Creatine kinase BB (CKBB;
ab38212), zinc ﬁnger protein 179 (ab42499), retinoic acid X receptor
gamma (ab15518), chitotriosidase (CHIT1; ab72574), and transferrin
(ab1223) antibodies came from Abcam (Cambridge, United Kingdom).
Beta-2-glycoprotein(MCA2114;AbDSerotec,Oxford,UnitedKingdom)
and complement C3 (C7761-1VL; Sigma-Aldrich, Poole, United King-
dom) antibodies were also used. Secondary antibodies were purchased
fromDako(Cambridge,UnitedKingdom)andNordicImmunology(Til-
burg, Netherlands).
(ii) Positive-control protein markers. The positive-control lysate
usedforcaspase3wasJurkatapoptosiscellstreatedwithetoposide(9663;
CellSignaling).ForAIF,CKBB,andRXRgamma,thepositive-controlcell
lysate was HeLa whole-cell lysate (sc-2200; Santa Cruz Biotechnology).
For zinc ﬁnger protein 179, the positive-control lysate used was HepG2
cell lysate (sc-2227; Santa Cruz Biotechnology). For chitotriosidase, a re-
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Minneapolis, MN).
Blood plasma (obtained from a healthy volunteer) was used as a con-
trol for complement C3, transferrin, and beta-2-glycoprotein. For trans-
ferrin, a recombinant transferrin protein was used as an additional posi-
tive control (Sigma-Aldrich; 90190).
Quantitative measure of protein expression in cerebrospinal ﬂuid.
The blot images were captured using a gel documentation camera (Syn-
gene, Cambridge, United Kingdom) and analyzed using the open source
software ImageJ (v.1.43; NIH, Bethesda, MD; free download available at
http://rsb.info.nih.gov/ij/) (47). In these Western blots, the reference
band used was the positive control for the protein under analysis. The
expression value obtained for CSF was converted to an approximate
quantity using a calibration curve generated from the positive control
(http://lukemiller.org/journal/2007/08/quantifying-western-blots
-without.html). This value was then converted to a native concentration
inCSFbycorrectionofthedilutionofCSFusedintheWesternblotassay.
ThequantityofproteinmeasuredwasestimatedforeachCSFsampleasa
relative intensity. Data regarding expression are given in Table S1 in the
supplemental material.
Quantitative analysis of transferrin and complement C3 in blood
serum. Analysis was performed on corresponding serum samples col-
lected as part of routine diagnosis. Analysis was performed using an im-
munoturbidimetric assay. Measurements were collected using a Cobas
c501 modular analyzer (Roche, West Sussex, United Kingdom). Preci-
norm protein kits (Roche) were used for both complement C3 and trans-
ferrinanalysis.ThemeasurementrangeforC3was0.9to1.8gliter1,and
that for transferrin was 2.0 to 3.6 g liter1.
Statistical analysis. Pairwise comparisons were performed using an
unpaired t test with Welch’s correction. This was calculated using Prism
software (v.5.0; GraphPad, La Jolla, CA).
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